Abstract:The current HBsAg vaccine has performed a vital role in preventing the transmission of HBV during the past 20 years. However, a number of individuals still show no response or a low response to the vaccine. In the present study, the HBV envelope large protein gene was cloned into the eukaryotic expression vector pPIC9k and was subsequently expressed in the yeast Pichia pastoris. The HBV large protein (L protein) was produced and secreted into the medium, where some of the L protein formed particles. The soluble L protein and particles were purified by column chromatography and sucrose density gradient centrifugation. Western blot analysis demonstrated that the particle was composed of both HBV L and S protein. To compare the antigenicity of the L protein and HBsAg, rabbits were immunized with the soluble L protein and the commercially available HBV vaccine and the increasing level of antibodies was determined by ELISA. The results showed that the anti-HBsAg antibody, from rabbits injected with the L protein at a dose of 2 and 10microg, was detected on day 14, whereas rabbits vaccinated with 10 and 2microg HBsAg did not develop antibodies until day 21 and 28, respectively. The antibody level in groups inoculated with the L protein was approximately 50% higher than in the group injected with HBsAg using the same dose. Furthermore, 2microg L protein induced a significant and rapid anti-HBsAg antibody response than 10microg HBsAg. Therefore, we suggest that the L protein is an ideal candidate for a new generation HB vaccine to protect people from HBV infection.

[Prokaryotic Expression and Polyclonal Antibody Preparation of Truncated Duck Hepatitis B Virus Core Protein].

Preparation and identification of duck hepatitis B virus core protein monoclonal antibody

Cloning, Expression and Purification of Duck Hepatitis B Virus (DHBV) Core Protein and Its Use in the Development of an Indirect ELISA for Serologic Detection of DHBV Infection

Construction of duck hepatitis B virus core antigen DNA vaccine and induced humoral immune response

Expression and purification of truncated C gene combined with preS1 gene from HBV in E.coli

Prokaryotic expression and purification of HBV targeted ribonuclease gene and preparation of its polyclonal antibody

Cloning and Expression of VP1 Gene of Duck Hepatitis Virus Genotype C and Preparation of Its Polyclonal Antibody

Recombinant Vaccinia Virus Expressing Pre-S/S Protein of Duck Hepatitis B Virus and Its Preliminary Use for Treatment of Persistent Infection.

Purification and Application of C-terminally Truncated Hepatitis C Virus E1 Proteins Expressed in Escherichia Coli.

Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus.

Preparation of Monoclonal Antibody against Duck Hepatitis Virus

Expression of recombinant VP1 protein of duck hepatitis virus 1 and screening of specific binding peptides

Prokaryotic Expression and Purification of Protein D of Haemophilus Influenza Type B

Production, purification and characterization of polyclonal antibody against the truncated gK of the duck enteritis virus

Expression of VP1 Gene of E53 Strain of Duck Hepatitis Virus Type 1 in Insect Cells and Analysis of the Expression Products

Establishment of the Quantitative Immunohistochemical Examination of DHBcAg in Duck Liver

Preparation and identification of monoclonal antibodies against locale isolated strain of duck hepatitis virus

Construction of Eukaryotic Expression Plasmids of Hepatitis B Surface Antigen and Helper T Lymphocyte Epitope

Prokaryotic Expression,antibody Preparation and Prelimary Application of Extracellular Region of CD3ε of Cherry Valley Duck

Expression, Purification and Characterization of the Hepatitis B Virus Entire Envelope Large Protein in Pichia Pastoris.

[Prokaryotic Expression of N-terminal Antigenic Domain of Duck Plague Virus Gb Protein and the Establishment of Putative Indirect ELISA Assay].